News
-
-
TIF Article: COVID-19 Pandemic Exacerbated Existing Problems With Thalassaemia Care
The article discusses how the COVID-19 pandemic has magnified challenges in thalassaemia care worldwide and underscores TIF’s activities throughout the coronavirus outbreak in support of patients with haemoglobinopathies. Hematology Advisor…
Read More » -
-
-
-
-
NEW PUBLICATION | Short Guide For the Management of TDT (2nd Edition)
The 4th edition of the original full-length Guidelines, published in June 2022, includes a full review of the evidence supporting almost each recommendation for physicians to know all the facts…
Read More » -
-
TIF Guide on COVID-19 Vaccinations & Therapeutic Drugs – The December Issue
During this last fortnight, experts have scrambled to gain an understanding of the new heavily mutated variant, what kind of symptoms and illness it can cause, and whether it undermines…
Read More » -
A milestone in the treatment of b-thalassaemia – The 1st gene therapy for Transfusion Dependent β-Thalassaemia wins approval in Europe
Zynteglo, Bluebird Bio’s ex vivo gene therapy for β-thalassaemia, got a green light from the EMA for conditional marketing authorization making it the 1st gene therapy for patients with…
Read More »